2020년 아젠다
Cambridge Healthtech Institute’s 15th Annual
Neurotech Investing & Partnering Conference
제휴, 투자, 협업 관계 구축에 의한 뉴로테크놀러지 분야에서의 연구개발 가속
2020년 5월 5-6일
Neurotech Investing & Partnering Conference는 뇌와 신경계의 새로운 치료법 및 진단법 개발에 참여하고 있는 투자자, 기업 임원, 기업가, 연구자 등이 한자리에 모여 소속 조직과 업계의 향후 발전을 위해 의견을 교환하면서 교류하는 국제적 포럼입니다.
향후 시장 동향 등에 대해 논의하는 이 컨퍼런스에서는 뉴로테크놀러지 업계의 현황에 관한 기조 강연, 최첨단 연구에 주력하고 있는 기업의 프레젠테이션, 주요 중개연구(translational research) 프로젝트의 소개, 뉴로테크놀러지 분야의 다양한 토픽에 초점을 맞춘 패널 디스커션 등이 진행됩니다.
Preliminary Agenda
State of the Neurotechnology Industry
Guest speakers provide an annual review of trends and developments in neuropharmaceuticals, neurodevices, and neurodiagnostics.
Speakers: Harry Tracy, PhD, President, NI Research
James Cavuoto, Editor & Publisher, Neurotech Reports
Investing in Neurotech Panel
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models
in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Panelist: Laura Tadvalkar, Principal, MP Healthcare Venture Management (MPH)
Jamil Beg, Principal, 5AM Ventures
Tom Mathers, Partner, Pappas Capital
Wasim Malik, Partner, Iaso Ventures
Treatments for Alzheimer’s and Cognitive Disorders
As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon
for symptom improvement and disease modification from drug and device companies? Can earlier or more accurate diagnosis improve outcomes?
Speaker: Casey Lynch, CEO, Cortexyme
New Modalities in Epilepsy
Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in epilepsy. Hear from leading companies on their approaches.
Moderator: Catherine Abbadie, PhD, Sr. Director, Business Development and Alliance Management, Sunovion
Speakers:
Ana Maiques, CEO, NeuroElectircs
Mark Lehmkuhle, CEO, Epitel
Internal and External Research and Development
Pharmaceutical and device companies are looking to provide complete solutions that span from prevention to treatment. Functions across the value chain will
be kept in house or partnered.
This panel of experts will discuss how they approach collaborations with other companies, academic groups, research institutes, and platform companies.
Moderator: Maria Shepherd, President, Medi-Vantage
Panelists:
Jeffrey Erb, Sr. Director, Strategy, and Business Development, Medtronic, Inc.
Bill Zeruld, Sr. Director, Alliance Management, Otsuka Pharmaceuticals
Parkinson’s and Other Movement Disorders
Current treatments for movement disorders can improve functioning but suffer from side effects and “off” periods especially as the disease progresses. A number of novel pipeline
pharmaceuticals and devices seek to address these issues. This session will explore how disease modifying treatments alter the course of movement disorders and how companion diagnostics can be leveraged to provide the most optimal outcomes for patients.
Moderator: Maria Shepherd, President, Medi-Vantage
Next-Generation Psychiatry
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric
illnesses represent a large portion of the neurotech market. Development of promising next-generation treatments is challenging.
Novel devices and diagnostics are poised to change the treatment landscape. This session will gather the most innovative treatments for mental health disorders.
Moderator: Manuel Lopez Figueroa, Venture Partner, Bay City Capital
Speakers:
John Kaiser, CEO, Evecxia Therapeutics
David Baker, CEO, Vallon Pharmaceuticals
Targeting Orphan Diseases
Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. This session will gather companies developing treatments
for ALS, lysosomal storage disorders, Huntington’s, and more.
Super Session: Investing, Partnering and Licensing in Neurotech Panel
Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will
discuss their areas of interest for investment, in-licensing novel therapeutics, devices and diagnostics and what they look for in a partner.
Panelists:
Olga Krylova, PhD, Director BD, Otsuka Pharmaceuticals
Valerie Photos, PhD, Operating Partner, Iaso Ventures
Beth Shafer, PhD, Head, Neuroscience Business Development, Takeda
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.
